Free Trial

Embecta Q1 2023 Earnings Report

Embecta logo
$19.82 -0.17 (-0.85%)
(As of 12/17/2024 ET)

Embecta EPS Results

Actual EPS
$0.93
Consensus EPS
$0.49
Beat/Miss
Beat by +$0.44
One Year Ago EPS
N/A

Embecta Revenue Results

Actual Revenue
$275.70 million
Expected Revenue
$261.77 million
Beat/Miss
Beat by +$13.93 million
YoY Revenue Growth
N/A

Embecta Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

A conspiracy Trump won’t unseal (Ad)

New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.

This is the untold, true story of God’s Investment.

Embecta Earnings Headlines

Embecta (NASDAQ:EMBC) and PAVmed (NASDAQ:PAVM) Critical Analysis
Contrasting Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ)
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
BTIG upgrades Embecta Corporation (EMBC) to a Buy
See More Embecta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email.

About Embecta

Embecta (NASDAQ:EMBC), a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

View Embecta Profile

More Earnings Resources from MarketBeat

Upcoming Earnings